Longeveron (LGVN) Cash from Investing Activities (QoQ) (2020 - 2026)
Longeveron (LGVN) Cash from Investing Activities (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Longeveron | 14.87 Bn | 14.86 Bn | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.75% |
| Dec 31, 2025 | 45.76% |
| Sep 30, 2025 | 55.13% |
| Jun 30, 2025 | -75.33% |
| Mar 31, 2025 | -21.95% |
| Dec 31, 2024 | 74.27% |
| Sep 30, 2024 | -801.89% |
| Jun 30, 2024 | -478.57% |
| Mar 31, 2024 | -99.10% |
| Dec 31, 2023 | -59.12% |
| Sep 30, 2023 | 56.16% |
| Jun 30, 2023 | 608.09% |
| Mar 31, 2023 | 160.70% |
| Dec 31, 2022 | 76.14% |
| Sep 30, 2022 | -257.69% |
| Jun 30, 2022 | 97.52% |
| Mar 31, 2022 | 158.33% |
| Dec 31, 2021 | 72.16% |
| Dec 31, 2020 | 0.00% |
| Sep 30, 2020 | 2.44% |